Share Buyback Program: DKK20 billion concluded. Novo Nordisk AS (NYSE:NVO) reported a strong 26% sales growth and 26% operating profit growth for 2024. The company expanded its patient reach ...

Novo Nordisk A/S today announced 2024 earnings ... If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Dividend Increase: 21% increase to DKK11.40 per share. Share Buyback Program: DKK20 billion concluded. Novo Nordisk AS (NYSE:NVO) reported a strong 26% sales growth and 26% operating profit growth for ...

Phase 3 results reported for CagriSema last month were a disappointment, however, with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a ...

If you’re looking to dramatically change a room but don’t want to spend a lot of money, time, or even be especially committed to the results, consider removable wallpaper — specifically the ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Novo Nordisk remains confident in CagriSema’s potential despite underwhelming Phase III results so far. Image credit: Shutterstock/ Kittyfly. Novo Nordisk is planning a new Phase III trial for ...

News, views and features on today's stories in Parliament ...

After hours: February 7 at 7:59:54 PM EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...